Commodore Capital reduced its Nuvalent stake by 850,000 shares (worth $83.81 million) in Q4 2025, cutting the position from 9.26% to 3.68% of assets. Despite the sale, Nuvalent shares are up 29% over the past year and the company maintains strong cash runway into 2029 with upcoming FDA catalysts including a PDUFA date for zidesamtinib in September.

Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.

Nuvalent, a clinical-stage biotechnology company, reported a Q2 2025 net loss of $99.7 million while advancing its oncology pipeline, focusing on kinase mutation therapies for lung cancer. The company continues developing zidesamtinib and neladalkib, with potential drug launches anticipated in 2026.

Nuvalent presented positive data from its Phase 1/2 trials for zidesamtinib and NVL-655 at the ESMO Congress 2024. The company plans to initiate a Phase 3 trial for NVL-655 in the first half of 2025 and expects pivotal data from both trials in 2025. Nuvalent also announced a $350 million public offering.

Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The dilution monster stalked the company following the announcement of a new capital-raising effort.

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of Oct. 6, 2023. Maison Solutions (NASDAQ: MSS): A fast-growing specialty retailer that offers traditional Asian food to U.S. consumers went public this week and saw interest from investors. The company offered 2.5 million shares at $4 each. Shares traded between $3.76 and $11.48 on Thursday for the company’s market debut and were halted several times. Low-float IPOs have been hot commodities during their first few days of public trading. The company plans on using proceeds to fund new store builds and potential acquisitions. Related Link: Ground Control To Congress, Commencing Countdown Engines Off: How ...

Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.

Within the last quarter, Nuvalent (NASDAQ:NUVL) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 0 0 Last 30D 0 2 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 1 1 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Nuvalent has an average price target of $59.5 with a high of $73.00 and a low of $42.00. Below is a summary of how these 6 analysts rated Nuvalent over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on ...Full story available on Benzinga.com

Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.

The company reported preliminary data on a non-small cell lung cancer therapy.

Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients, has proven unprofitable for approximately two years.  The analyst keeps the price target of $65, with a Buy rating. The analyst notes that historically, such updates have resulted in low Objective Response Rates (ORRs) and short-lived efficacy, rendering late-stage market sales relatively inconsequential.  Moreover, these drugs have often failed to distinguish themselves from entrenched, highly effective first-line (1L) standards of care. However, a noteworthy exception arises in ALK+ Non-Small Cell Lung Cancer (NSCLC), where the preference for the older-generation TKI, Genetech's Alecensa (alectinib), persists over the considerably more potent Pfizer ...Full story available on Benzinga.com